141: The Prognostic Significance of Lymphocyte-to-CRP Ratio (LCR) in Patients With COVID-19

Ahsan, Muhammad; Kurpad, Krishna Prasad; Mehta, Harsh; Bayambe, Santhosh; Nair, Archana Sreekantan; Gandhi, Krupa; Maharaul, Mashrutee; Gopal, Shwetha; Kulkarni, Rohit; Kumar, Amit; Rezai, Fariborz; Yodice, Paul; Fless, Kristin; Ovnanian, Vagram; Safford, Mark; Mistry, Nirav

doi:10.1097/01.ccm.0000726452.58093.aa

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than three years after the outbreak of the COVID-19 pandemic, a scoring system for evaluating disease severity in this group of patients has not yet been developed. [23][24][25][26] The clinical state of hospitalized COVID-19 patients is evaluated with the use of generic scoring systems, such as the MEWS. 27 This study was undertaken to determine the presence of correlations between the severity of COVID-19 symptoms based on the MEWS and inflammatory markers.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Inflammatory Markers (CRP, IL6, CRP/IL6, CRP/L, LCR) for Assessing the Severity of COVID-19 Symptoms Based on the MEWS and Predicting the Risk of Mortality

Wolszczak-Biedrzycka¹,

Zińczuk²,

Milewska³

et al. 2023

JIR

View full text Add to dashboard Cite

Various diagnostic tools are used to assess the severity of COVID-19 symptoms and the risk of mortality, including laboratory tests and scoring indices such as the Modified Early Warning Score (MEWS). The diagnostic value of inflammatory markers for assessing patients with different severity of COVID-19 symptoms according to the MEWS was evaluated in this study. Materials and Methods:The concentrations of CRP (C-reactive protein) (immunoassay) and IL6 (interleukin 6) (electrochemiluminescence assay) were determined, and CRP/IL6, CRP/L, and LCR ratios were calculated in blood serum samples collected from 374 COVID-19 patients. Results: We demonstrated that CRP, IL6, CRP/IL6, CRP/L, LCR inflammatory markers increase significantly with disease progression assessed based on the MEWS in COVID-19 patients and may be used to differentiating patients with severe and non-severe COVID-19 and to assess the mortality. Conclusion:The diagnostic value of inflammatory markers for assessing the risk of mortality and differentiating between patients with mild and severe COVID-19 was confirmed.

show abstract

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Inflammatory Markers (CRP, IL6, CRP/IL6, CRP/L, LCR) for Assessing the Severity of COVID-19 Symptoms Based on the MEWS and Predicting the Risk of Mortality

Wolszczak-Biedrzycka¹,

Zińczuk²,

Milewska³

et al. 2023

JIR

View full text Add to dashboard Cite

show abstract

“…El seguimiento de los pacientes se realiza hasta los 30 días de estancia en UCI. Se evalúo a la mortalidad como variable de respuesta, siendo la variable de exposición a L/PCR elevado como un valor medido al ingreso como mayor a 100 ( (Henry et al, 2020;Ahsan et al, 2021). Se planteó un adecuado control de las principales variables confusoras como sexo, edad, variables laboratoriales como dímero D (elevado si > 500ng/ml), hiperlactatemia (si > 2 mmol/l), LDH (elevado si > 450 UI/l), plaquetopenia (si < 150 000/m3), también variables clínicas importantes asociadas a mortalidad del paciente crítico como necesidad de terapia de reemplazo renal (NTRR), shock, carga de comorbilidades a través del escore de Charlson.…”

Section: Materiales Y Métodosunclassified

“…El L/PCR se reduce significativamente en los casos graves, lo que sugiere que este marcador podría reflejar la gravedad de COVID-19, esto debido a que el equilibrio entre la respuesta inmunitaria del huésped y la respuesta hiperinflamatoria juega un papel clave en el pronóstico de la enfermedad COVID-19 (Sun et al, 2020). Niveles más bajos de L/PCR en pacientes graves podrían ser resultado de menos linfocitos que conducen a una disfunción inmunológica y niveles más altos de PCR que reflejan la gravedad sistémica de respuesta inflamatoria de los pacientes ( Henry et al, 2020;Ahsan et al, 2021). Por ello, el objetivo del estudio fue determinar que el índice linfocito/proteína C reactiva disminuida es factor pronóstico de mortalidad en pacientes con COVID-19.…”

Section: Introductionunclassified

Índice linfocito/proteína C reactiva disminuido como factor pronóstico de mortalidad en pacientes con COVID-19

Enriquez

2023

BMSA

View full text Add to dashboard Cite

The objective of this study was to determine that the decreased lymphocyte/C-reactive protein (L/CRP) ratio is a prognostic factor for mortality in patients with COVID-19. The research had an analytical, observational, retrospective and longitudinal cohort design carried out in 93 patients. The frequency distribution data of qualitative variables and the measures of centralization and dispersion of quantitative variables were obtained. In addition, the Chi Square (X2) test was used, therefore, the associations were considered significant if p was less than 0.05. Finally, among the qualitative variables, the relative risk of the L/CRP index with respect to the risk of mortality in COVID-19 was calculated. Afterwards, the multivariate analysis was carried out with logistic regression for the intervening variables that were significant in the bivariate analysis. In the results, of the 93 patients, it was possible to show that 44.1% died. In addition to this, it was found that age over 60 years, normal lymphocyte counts and decreased values of the L/CRP Index proved to be a risk factor for mortality in patients with COVID-19. In conclusion, the decreased L/CRP ratio is a prognostic factor for mortality in patients with COVID-19.

show abstract

141: The Prognostic Significance of Lymphocyte-to-CRP Ratio (LCR) in Patients With COVID-19

Cited by 2 publications

References 0 publications

The Diagnostic Value of Inflammatory Markers (CRP, IL6, CRP/IL6, CRP/L, LCR) for Assessing the Severity of COVID-19 Symptoms Based on the MEWS and Predicting the Risk of Mortality

The Diagnostic Value of Inflammatory Markers (CRP, IL6, CRP/IL6, CRP/L, LCR) for Assessing the Severity of COVID-19 Symptoms Based on the MEWS and Predicting the Risk of Mortality

Índice linfocito/proteína C reactiva disminuido como factor pronóstico de mortalidad en pacientes con COVID-19

Contact Info

Product

Resources

About